Affluent Medical

🔥 𝐍𝐄𝐖𝐒⎢1st successful human implantation of our Artus artificial sphincter for the treatment of stress urinary incontinence 🎉 This is another major milestone for Affluent Medical and the hope of a better life for the 400 million people suffering from urinary incontinence worldwide 🌎 ℹ️ 𝑨𝒃𝒐𝒖𝒕 𝑨𝒓𝒕𝒖𝒔:  Artus is an innovative device: an implantable artificial urinary sphincter designed specifically to treat moderate to severe urinary incontinence in men and women. This device, which regulates the opening and closing of the urethra, is activated by the patient using a remote control. Its design has been conceived to adapt perfectly to each patient's individual lifestyle, offering a personalised, effective solution. 𝑭𝒐𝒄𝒖𝒔 𝒐𝒏 𝒕𝒉𝒆 𝒑𝒓𝒐𝒄𝒆𝒅𝒖𝒓𝒆:  👤𝘗𝘢𝘵𝘪𝘦𝘯𝘵: Male, 68 years old, suffering from severe urinary incontinence.  👨⚕️𝘊𝘩𝘪𝘳𝘶𝘳𝘨𝘪𝘦𝘯 : Pr Roman Zachoval, MD, PhD head of the urology department at Thomayer University Hospital in Prague carried out the operation under the supervision of Professor Nicolas Barry Delongchamps, professor of urology at Cochin University Hospital in Paris.  📊 𝘙𝘦𝘴𝘶𝘭𝘵: The patient is doing well and was discharged from hospital 5 days after the operation, without any complications!  👉 𝘕𝘦𝘹𝘵 𝘴𝘵𝘦𝘱: Activation of the device in 6 weeks, as soon as wound healing is complete! ➡️ Swipe to discover Pr Roman Zachoval's testimonial after the operation! 🎉 Congratulation to the entire team of Artus for reaching this important milestones ! Marion Mélot Benjamin Renault - PhD, MBA, 6σ-Black B. Christophe Giot Stay tuned for more on this medical breakthrough! 👋 Sebastien Ladet, Ph.D. Michel Therin Truffle Capital #IncontinenceUrinaire #Innovation #Medtech #Artus #sante

🚀 𝐒𝐓𝐀𝐑𝐓𝐔𝐏⎢Affluent Medical s’allie au groupe 🇺🇸 Edwards Lifesciences et décroche 15 millions d’euros pour ses technologies de valve mitrale🔥👇 Jackpot pour Affluent Medical, medtech de notre territoire 💸 L’entreprise, spécialisée dans le développement et l’industrialisation de dispositifs médicaux innovants, a signé plusieurs accords avec le grand groupe américain Edwards Lifesciences 🤝 ✅ Ces accords concernent les produits d'Affluent Medical, notamment l'anneau mitral ajustable Kalios, ainsi que sa technologie de valve mitrale en cardiologie structurelle. 🔥 Grâce à cette récente opération, Affluent recevra un financement de 15 millions d’euros répartis de la manière suivante : 💸 5 millions d’euros d’augmentation de capital  💸 5 millions d’euros d’option d’achat de son anneau mitral Kalios  💸 5 millions d’euros de licence sur sa technologie mondiale 💬 « 𝑁𝑜𝑢𝑠 𝑠𝑜𝑚𝑚𝑒𝑠 𝑓𝑖𝑒𝑟𝑠 𝑑𝑒 𝑠𝑖𝑔𝑛𝑒𝑟 𝑐𝑒𝑠 𝑎𝑐𝑐𝑜𝑟𝑑𝑠 𝑎𝑣𝑒𝑐 𝑙𝑒 𝑙𝑒𝑎𝑑𝑒𝑟 𝑚𝑜𝑛𝑑𝑖𝑎𝑙 𝑑𝑒 𝑙’𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 𝑒𝑛 𝑚𝑎𝑡𝑖𝑒̀𝑟𝑒 𝑑𝑒 𝑐𝑎𝑟𝑑𝑖𝑜𝑙𝑜𝑔𝑖𝑒 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑙𝑙𝑒. 𝑁𝑜𝑢𝑠 𝑛𝑜𝑢𝑠 𝑟𝑒́𝑗𝑜𝑢𝑖𝑠𝑠𝑜𝑛𝑠 𝑑’𝑎𝑐𝑐𝑢𝑒𝑖𝑙𝑙𝑖𝑟 𝐸𝑑𝑤𝑎𝑟𝑑𝑠 𝑒𝑛 𝑡𝑎𝑛𝑡 𝑞𝑢’𝑎𝑐𝑡𝑖𝑜𝑛𝑛𝑎𝑖𝑟𝑒 𝑑𝑒 𝑛𝑜𝑡𝑟𝑒 𝑠𝑜𝑐𝑖𝑒́𝑡𝑒́. 𝐿𝑎 𝑓𝑜𝑟𝑡𝑒 𝑝𝑟𝑒́𝑠𝑒𝑛𝑐𝑒 𝑑’𝐸𝑑𝑤𝑎𝑟𝑑𝑠 𝑠𝑢𝑟 𝑙𝑒 𝑚𝑎𝑟𝑐ℎ𝑒́ 𝑚𝑜𝑛𝑑𝑖𝑎𝑙 𝑒𝑡 𝑠𝑜𝑛 𝑖𝑛𝑓𝑟𝑎𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒 𝑐𝑜𝑚𝑚𝑒𝑟𝑐𝑖𝑎𝑙𝑒 𝑜𝑓𝑓𝑟𝑒𝑛𝑡 𝑙𝑎 𝑝𝑜𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑒́ 𝑎̀ 𝑛𝑜𝑡𝑟𝑒 𝑝𝑟𝑜𝑑𝑢𝑖𝑡 𝐾𝑎𝑙𝑖𝑜𝑠™ 𝑑’𝑎𝑐𝑐𝑜𝑚𝑝𝑎𝑔𝑛𝑒𝑟 𝑙𝑒𝑠 𝑚𝑒́𝑑𝑒𝑐𝑖𝑛𝑠 𝑒𝑡 𝑙𝑒𝑢𝑟𝑠 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑑𝑎𝑛𝑠 𝑙𝑒 𝑚𝑜𝑛𝑑𝑒 𝑒𝑛𝑡𝑖𝑒𝑟, 𝑡𝑜𝑢𝑡 𝑒𝑛 𝑒́𝑡𝑎𝑏𝑙𝑖𝑠𝑠𝑎𝑛𝑡 𝑢𝑛 𝑝𝑎𝑟𝑡𝑒𝑛𝑎𝑟𝑖𝑎𝑡 𝑠𝑜𝑙𝑖𝑑𝑒 𝑝𝑜𝑢𝑟 𝐾𝑎𝑙𝑖𝑜𝑠™ 𝑒𝑡 𝑙𝑒𝑠 𝑣𝑎𝑙𝑣𝑒𝑠 𝑚𝑖𝑡𝑟𝑎𝑙𝑒𝑠 𝑐ℎ𝑖𝑟𝑢𝑟𝑔𝑖𝑐𝑎𝑙𝑒𝑠 𝑢𝑡𝑖𝑙𝑖𝑠𝑎𝑛𝑡 𝑛𝑜𝑡𝑟𝑒 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑖𝑒.  𝐴𝑓𝑓𝑙𝑢𝑒𝑛𝑡 𝑐𝑜𝑛𝑡𝑖𝑛𝑢𝑒𝑟𝑎 𝑑𝑒 𝑑𝑒́𝑣𝑒𝑙𝑜𝑝𝑝𝑒𝑟 𝑠𝑎 𝑣𝑎𝑙𝑣𝑒 𝑚𝑖𝑡𝑟𝑎𝑙𝑒 𝑡𝑟𝑎𝑛𝑠𝑐𝑎𝑡ℎ𝑒́𝑡𝑒𝑟 𝐸𝑝𝑦𝑔𝑜𝑛 𝑒𝑡 𝑠𝑜𝑛 𝑠𝑝ℎ𝑖𝑛𝑐𝑡𝑒𝑟 𝑎𝑟𝑡𝑖𝑓𝑖𝑐𝑖𝑒𝑙 𝑝𝑜𝑢𝑟 𝑙’𝑖𝑛𝑐𝑜𝑛𝑡𝑖𝑛𝑒𝑛𝑐𝑒 𝑢𝑟𝑖𝑛𝑎𝑖𝑟𝑒 𝐴𝑟𝑡𝑢𝑠. » Sebastien Ladet, Ph.D. - CEO d’Affluent Medical. 🚀 𝑨 𝒑𝒓𝒐𝒑𝒐𝒔 𝒅’𝑨𝒇𝒇𝒍𝒖𝒆𝒏𝒕 𝑴𝒆𝒅𝒊𝒄𝒂𝒍 :  Actuellement en phase clinique, Affluent Medical développe des implants de nouvelle génération, très peu invasifs, innovants, ajustables et biomimétiques pour traiter des maladies cardiaques structurelles, ainsi que l’incontinence urinaire. Bravo Affluent Medical pour cette grande avancée 👏 Pour en savoir   🔗 https://lnkd.in/etzF8SPu 

Breaking news - Affluent Medical has signed several agreements related to our mitral product and technology. Under these agreements, Affluent will receive an upfront payment of 15 million euros. For more information, see the PR attached. Christophe de VREGILLE, Benjamin Renault, Christophe Giot, Michel Therin, Dr Philippe Pouletty, Samuel Pallotto, Vladimir Ganem, Suzy Delpierre, Mathilde Razou, Ghislaine Gasparetto, Fieldfisher, SEITOSEI.ACTIFIN | Finance & Corporate Communication, MC Services AG, Agili(3f), PwC,EXPERTEA

🎤 Régulièrement, je vous propose de partir à la rencontre d’un acteur ou d’une innovation du digital santé en France. Aujourd’hui partons à la rencontre de Sebastien Ladet, Ph.D. Directeur Général d’Affluent Medical pour parler d’innovation au service des patients. "Nous proposons des produits très innovants qui sont le fruit d’une collaboration étroite entre des médecins, des chirurgiens et des ingénieurs" "Ce qui est donc au cœur de notre mission, c’est de travailler sur des solutions implantables, en s’inspirant de l’anatomie humaine, ajustables et qui permettent de réduire l’impact des chirurgies pour le patient et d’améliorer significativement leur vie." " J’ai été surpris par le dynamisme de l’écosystème Français avec de nombreuses start-up innovantes." 👉 Des échanges à retrouver sur Buzz E-santé : https://lnkd.in/ewHJXXN2 Interview réalisée en partenariat avec Affluent Medical #medtech #esante Francois Laborde Jean-Christophe PERLES Christophe Giot Vincent Gardès Claire André William ROLLAND Benjamin Renault - PhD, MBA, 6σ-Black B. Christophe de VREGILLE Denise Silber LIONEL REICHARDT Chanfi MAOULIDA, MBA Julien Delpech Jérôme LELEU Franck LE MEUR Adel Mebarki Eric Vibert, MD, PhD David Mercier Laurent Mignon Didier MENNECIER 🩺 Pascal BECACHE Anca Petre Vincent Montet Eric Phélippeau Fabrice DENIS Juliette Da Mota Rocha Roxane Philippe Luc Soler Dr Solène Vo Quang Lucile LIM NOYELLE Delphine LALANDE

🔥𝐍𝐄𝐖𝐒⎢Artus artificial urinary sphincter meets pilot clinical objective on first 2 patients 🔥👇 This is a promising step forward during this World Incontinence Week 🚀 🎉 Already 2️⃣ patients have now been successfully implanted with our Artus artificial urinary sphincter. A look back at this 2nd operation which took place in Poland 👇 👤 𝑷𝒂𝒕𝒊𝒆𝒏𝒕: 70-year-old man suffering from urinary incontinence.  ⏱ 𝑶𝒑𝒆𝒓𝒂𝒕𝒊𝒏𝒈 𝒕𝒊𝒎𝒆: 45 min  🧑🏻⚕️ 𝑷𝒓𝒐𝒄𝒆𝒅𝒖𝒓𝒆 𝒑𝒆𝒓𝒇𝒐𝒓𝒎𝒆𝒅 𝒃𝒚 : Professor Piotr Chłosta → Urologist → Chairman of the Department of Urology at the Faculty of Medicine of the Jagiellonian University in Kraków → Head of the Clinical Department at the University Hospital in Kraków. 𝑹𝒆𝒔𝒖𝒍𝒕𝒔 𝒐𝒃𝒕𝒂𝒊𝒏𝒆𝒅 𝒐𝒏 𝒕𝒉𝒆 2 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔:  ✅ Successful activation of the Artus devices 6 weeks after each surgery. ✅ Safety criteria achieved, and no discomfort or pain reported by patients. 🔥 The Affluent Medical team is very proud to announce these positive preliminary results of our innovative solution 💪 This is another important milestone for our company and its ambition to improve the lives of nearly 400 million people suffering from urinary incontinence worldwide!  For more information  🇫🇷 https://lnkd.in/gQhxj7Dv 🇬🇧 https://lnkd.in/gmGWbva2

📊 Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group📈 👇 Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024. In this study, Société de Bourse Gilbert Dupont recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024. This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside ✅ Invest Securities ✅ Kepler Cheuvreux ✅ Portzamparc Groupe BNP Paribas  ✅ TP ICAP Midcap #Innovation #MedTech 

📊 Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group📈 👇 Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024. In this study, Société de Bourse Gilbert Dupont recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024. This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside ✅ Invest Securities ✅ Kepler Cheuvreux ✅ Portzamparc Groupe BNP Paribas  ✅ TP ICAP Midcap #Innovation #MedTech 

On my way to Dublin for the Innovation summit 2024. Great conference to meet investors, strategics and key providers to support start up companies. Looking forward to it! MedTech Strategist Affluent Medical #medtech

Thank you to Laure Belot and Le Monde to highligh French innovation following the first in human of Artus - Affluent Medical's artificial urinary sphincter. The innovation leading to this point has been supported by our founder and main investor Truffle Capital during a ten year journey. The new generation of urinary sphincter as Artus is the promess for a better quality of life for hundred of millions of people suffering from urinary incontinence across the world. Marion Mélot, Benjamin Renault, Christophe Giot, Christophe de VREGILLE, Michel Therin, Truffle Capital SEITOSEI.ACTIFIN | Finance & Corporate Communication, Jennifer Jullia, Ghislaine Gasparetto, Alexandre COMMEROT

📊  Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap 📈👇 TP ICAP Midcap's study "Du baume au cœur", published on 27 March 2024, announces a potential upside of 87% compared with the closing price on 26 March 2024 🚀🔥 This new milestone represents significant recognition of our growth and potential in the market. This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, and Portzamparc Groupe BNP Paribas.    🇫🇷 https://lnkd.in/grZifjsw   🇬🇧 https://lnkd.in/gDtdjnff   #Innovation #MedTech